Human plasma-derived fibrinolysin (Grifols)

Grifols have announced proof-of-concept data from its Chronos-PD programme, which uses AI, advanced proteomics and real-world data to identify early signs of Parkinson’s disease (PD). The data demonstrates that individuals with PD experience biological changes over a decade before clinical diagnosis, allowing for potential early diagnosis and intervention in the future. Affecting nearly one million people in the US and nearly six million worldwide, PD occurs when the brain cells that make dopamine stop working or die. Understanding of the causes of the disease remains limited despite decades of research and treatment advancement. Funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the study is the most deeply profiled longitudinal proteomic study in PD to date, with over 2,600 longitudinal plasma samples and over 25,000 protein types analysed using four complementary proteomics platforms. After analysing longitudinal plasma samples covering a period of up to 12 years before the diagnosis of PD and nine years afterwards in the pilot study, researchers were able to track the evolution of distinct plasma proteins in people with PD. This information has the potential to help establish an early-warning system for PD. Researchers have confirmed PD biomarkers previously discovered and identified reproducible early PD biomarkers, validated across up to five independent cohorts. The study also uncovered novel, early biomarkers of PD, including a major modulation of the CXCL12–cell adhesion molecules–integrin axis, a signalling network that governs leukocyte trafficking and blood-brain barrier integrity and is implicated in PD-associated neuroinflammation. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Office, said: “This new proof-of-concept data offers additional insights into the biology and progression of PD, years before clinical detection. “The results also validate the Chronos platform, with potential applications beyond PD. Going back in time to search for the earliest signs of disease can help accelerate and ultimately develop new diagnostics and disease-modifying therapeutics.”

The information is aimed exclusively at authorized healthcare professionals to prescribe or supply medical products and its correct interpretation requires specialized training. Are you a healthcare professional? THROMBATE III is now the only antithrombin concentrate (ATc) approved for hereditary antithrombin deficiency (hATd) in both adult and pediatric patients FDA approval was based on submitted data extrapolation from two clinical trials in adult patients addressing critical gaps in the clinical comprehension and treatment of pediatric hATd The expanded label for THROMBATE III indicates it can be safely and effectively used in pediatric patients with hATd, a rare patient population Barcelona, Spain, November 18, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that the United States Food and Drug Administration (FDA) has approved an expanded indication for THROMBATE III®, the company’s antithrombin III [human concentrate], to include pediatric patients diagnosed with hereditary antithrombin deficiency (hATd). With this expansion, THROMBATE III becomes the first and only antithrombin concentrate (ATc) approved for adults and pediatrics with hATd, a frequently undiagnosed blood clotting disorder that may affect up to 700,000 people in the U.S. People with this condition have a higher-than-average risk of developing abnormal blood clots. Considering that hATd has one of the highest thrombotic risks of all of the inherited thrombophilias1 and 85% of patients with hATd will have at least one thrombotic episode by age 502, this approval represents a significant step forward for patients and families impacted by hATd. “This label expansion helps close a long-standing gap in the treatment of pediatric patients with hereditary antithrombin deficiency,” said George M. Rodgers, III, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah School of Medicine. “It gives clinicians added confidence that ATc can be appropriately used in children.” FDA approval was supported by the extrapolation of data from two clinical studies in adult patients, concluding that ATc – which has been successfully used for treatment in adults with hATd for over three decades – can be safely and effectively used in pediatric patients with hATd. “Expanding the indication to include pediatric patients provides a new option for children and families facing hereditary antithrombin deficiency,” said Roland Wandeler, president of Grifols Biopharma. “This is another example of Grifols’ continuing work to provide more patients with medicines to enhance their health and well-being.” Treatment and prevention of thromboembolism in patients with hATd typically requires anticoagulation, with replacement of antithrombin (AT) with antithrombin sources like ATc or fresh frozen plasma (FFP) administration in certain high-risk situations. THROMBATE III has been approved in the U.S. for treatment of adults with hATd since 1991. About THROMBATE III® Clinical studies have shown that THROMBATE III is an effective choice for patients with hereditary antithrombin deficiency (hATd) and for the treatment and prevention of thromboembolism, including before, during, and after surgery and childbirth. THROMBATE III (antithrombin III [human]) is indicated in adult and pediatric patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism. Important Safety Information Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment. Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product. Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays. In clinical studies, the most common adverse reactions (≥ 5% of patients) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps). The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III. Please see accompanying full Prescribing Information for THROMBATE III®. Product information, including indications, safety warnings, and prescribing details, may vary by country. For information specific to your region, please consult your local regulatory authority or healthcare provider. 1 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):1229-1239 2 Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126(11):1326-1336 Our media relations team can be reached at: (+34) 93 571 00 02 media@grifols.com. Restricted to media inquiries only. For general questions and requests, please contact corporatecomms@grifols.com.